These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17525529)

  • 21. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
    Herrera-Abreu MT; Palafox M; Asghar U; Rivas MA; Cutts RJ; Garcia-Murillas I; Pearson A; Guzman M; Rodriguez O; Grueso J; Bellet M; Cortés J; Elliott R; Pancholi S; Baselga J; Dowsett M; Martin LA; Turner NC; Serra V
    Cancer Res; 2016 Apr; 76(8):2301-13. PubMed ID: 27020857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory.
    Lelliott EJ; Kong IY; Zethoven M; Ramsbottom KM; Martelotto LG; Meyran D; Zhu JJ; Costacurta M; Kirby L; Sandow JJ; Lim L; Dominguez PM; Todorovski I; Haynes NM; Beavis PA; Neeson PJ; Hawkins ED; McArthur GA; Parish IA; Johnstone RW; Oliaro J; Sheppard KE; Kearney CJ; Vervoort SJ
    Cancer Discov; 2021 Oct; 11(10):2582-2601. PubMed ID: 33990344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
    Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
    Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
    Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
    J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
    Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
    Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
    Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
    J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
    Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
    Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
    Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
    Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
    Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
    Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
    Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
    Marzec M; Kasprzycka M; Lai R; Gladden AB; Wlodarski P; Tomczak E; Nowell P; Deprimo SE; Sadis S; Eck S; Schuster SJ; Diehl JA; Wasik MA
    Blood; 2006 Sep; 108(5):1744-50. PubMed ID: 16690963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment.
    Liu N; Fang H; Li Y; Xu W
    Curr Med Chem; 2009; 16(36):4869-88. PubMed ID: 19929781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
    Baughn LB; Di Liberto M; Wu K; Toogood PL; Louie T; Gottschalk R; Niesvizky R; Cho H; Ely S; Moore MA; Chen-Kiang S
    Cancer Res; 2006 Aug; 66(15):7661-7. PubMed ID: 16885367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
    Olmez I; Brenneman B; Xiao A; Serbulea V; Benamar M; Zhang Y; Manigat L; Abbas T; Lee J; Nakano I; Godlewski J; Bronisz A; Abounader R; Leitinger N; Purow B
    Clin Cancer Res; 2017 Nov; 23(22):6958-6968. PubMed ID: 28814434
    [No Abstract]   [Full Text] [Related]  

  • 38. Identification of a novel TIF-IA-NF-κB nucleolar stress response pathway.
    Chen J; Lobb IT; Morin P; Novo SM; Simpson J; Kennerknecht K; von Kriegsheim A; Batchelor EE; Oakley F; Stark LA
    Nucleic Acids Res; 2018 Jul; 46(12):6188-6205. PubMed ID: 29873780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small interfering RNA targeting Rac1 sensitizes colon cancer to dihydroartemisinin-induced cell cycle arrest and inhibited cell migration by suppressing NFκB activity.
    Han P; Luan Y; Liu Y; Yu Z; Li J; Sun Z; Chen G; Cui B
    Mol Cell Biochem; 2013 Jul; 379(1-2):171-80. PubMed ID: 23559092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.